• LAST PRICE
    12.2900
  • TODAY'S CHANGE (%)
    Trending Up0.2400 (1.9917%)
  • Bid / Lots
    11.8500/ 2
  • Ask / Lots
    12.5000/ 5
  • Open / Previous Close
    12.0600 / 12.0500
  • Day Range
    Low 11.8800
    High 12.4800
  • 52 Week Range
    Low 3.0000
    High 13.6600
  • Volume
    391,395
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Line Graph See accessible table below
News Volume Accessibility Table
DateIndex Fund Price vs. News Density
03/2$11.73
03/3$11.78
03/6$11.78
03/7$11.81
03/8$11.53
03/9$11.42
03/10$11.39
03/13$11.47
03/14$11.71
03/15$11.55
03/16$11.76
03/17$11.60
03/20$11.50
03/21$11.56
03/22$11.73
03/23$11.87
03/24$12.03
03/27$12.12
03/28$12.10
03/29$12.20
03/30$12.05
03/31$12.29
  • Mar 22, 2023

  • Mar 9, 2023

      Show headlines and story abstract
    • 4:41PM ET on Thursday Mar 09, 2023 by Thomson Reuters
      Companies Mentioned: MACK

      March 9 (Reuters) - Merrimack Pharmaceuticals Inc:

      * MERRIMACK REPORTS FULL YEAR 2022 FINANCIAL RESULTS

      * MERRIMACK PHARMACEUTICALS INC - EXPECT THAT CA...

    • 4:40PM ET on Thursday Mar 09, 2023 by Business Wire
      Companies Mentioned: MACK

      Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022.

      "We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in November 2022 and the guidance that Ipsen has subsequently provided regarding its intention to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde(R) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"), which could lead to a potential future milestone payment from Ipsen" said Gary Crocker, CEO and Chairman of Merrimack's Board of Directors. "As a result of the exercise of stock options during the fourth quarter of 2022 and continued reductions in our operating expenses during 2022 we expect that our cash and cash equivalents as of December 31, 2022, will be sufficient to continue our operations beyond 2027, which we estimate to be the latest date when the longest-term potential Ipsen milestone may be achieved."

Peers Headlines